These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 11650029)

  • 1. Private rights to adulterated/misbranded articles.
    McMonagle L
    AIDS Public Policy J; 1987; 2(2):33-49. PubMed ID: 11650029
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA treatment use regulations: a compassionate response.
    Weitzman SA; Marcy T
    AIDS Public Policy J; 1987; 2(2):22-32. PubMed ID: 11650028
    [No Abstract]   [Full Text] [Related]  

  • 3. The right of privacy in choosing medical treatment: should terminally ill persons have access to drugs not yet approved by the Food and Drug Administration?
    Power SH
    John Marshall Law Rev; 1987; 20(4):693-714. PubMed ID: 11650094
    [No Abstract]   [Full Text] [Related]  

  • 4. Getting new drugs to people with AIDS: a public policy response to Lansdale.
    Cohen MN
    Hastings Constit Law Q; 1991; 18(3):471-85. PubMed ID: 11651493
    [No Abstract]   [Full Text] [Related]  

  • 5. The uncertain application of the right of privacy in personal medical decisions: the Laetrile cases.
    Christensen J
    Ohio State Law J; 1981; 42(2):523-50. PubMed ID: 11649547
    [No Abstract]   [Full Text] [Related]  

  • 6. AIDS treatment drugs: clinical trials and compassionate use.
    Levine RJ
    AIDS Public Policy J; 1987; 2(2):6-8. PubMed ID: 11650031
    [No Abstract]   [Full Text] [Related]  

  • 7. Laetrile and the privacy right in decisional responsibility.
    Volzer HJ
    Med Trial Tech Q; 1980; 27(4):395-429. PubMed ID: 11662802
    [No Abstract]   [Full Text] [Related]  

  • 8. Equitable access to biomedical advances: getting beyond the rights impasse.
    Mariner WK
    Conn Law Rev; 1989; 21(3):571-603. PubMed ID: 11650430
    [No Abstract]   [Full Text] [Related]  

  • 9. Laetrile: the battle moves into the courtroom.
    Schwartz RL
    Am Bar Assoc J; 1979 Feb; 65():224-8. PubMed ID: 11661617
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulation of drug treatments for HIV and AIDS: a contractarian model of access.
    Salbu SR
    Yale J Regul; 1994; 11(2):401-53. PubMed ID: 11660141
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental drugs: more of them, but they're no longer free.
    Caplan J
    Hastings Cent Rep; 1987 Jun; 17(3):3. PubMed ID: 11644019
    [No Abstract]   [Full Text] [Related]  

  • 12. AIDS: at the limits of the law.
    Wertheimer E
    Villanova Law Rev; 1989 Sep; 34(5):755-69. PubMed ID: 11651161
    [No Abstract]   [Full Text] [Related]  

  • 13. Implications of the federal drug investigation and approval processes for the development and availability of AIDS treatments and vaccines.
    Mathers PR
    AIDS Public Policy J; 1987; 2(2):50-3. PubMed ID: 11650030
    [No Abstract]   [Full Text] [Related]  

  • 14. Faith (healing), hope and charity at the FDA: the politics of AIDS drug trials.
    Annas GJ
    Villanova Law Rev; 1989 Sep; 34(5):771-97. PubMed ID: 11651162
    [No Abstract]   [Full Text] [Related]  

  • 15. Making experimental drugs available for AIDS treatment.
    Krim M
    AIDS Public Policy J; 1987; 2(2):1-5. PubMed ID: 11650026
    [No Abstract]   [Full Text] [Related]  

  • 16. Freedom of choice in medical treatment: reconsidering the efficacy requirement of the FDCA.
    Clinite BJ
    Loyola Univ Chic Law J; 1977; 9(1):205-26. PubMed ID: 11661566
    [No Abstract]   [Full Text] [Related]  

  • 17. In business to treat cancer.
    Henig RM
    N Y Times Mag; 1986 Nov; ():68, 70, 78, 80+. PubMed ID: 11647805
    [No Abstract]   [Full Text] [Related]  

  • 18. Off the pedestal and into the arena: toward including women in experimental protocols.
    Gorenberg H; White A
    Rev Law Soc Change; 1991-1992; 19(1):205-46. PubMed ID: 11659599
    [No Abstract]   [Full Text] [Related]  

  • 19. AIDS in the workplace: public and corporate policy.
    Heacock MV; Orvis GP
    Harv J Law Public Policy; 1990; 13(2):689-713. PubMed ID: 11656268
    [No Abstract]   [Full Text] [Related]  

  • 20. Perspectives on the FDA status of drug products manufactured by the recombinant DNA technique.
    Korwek EL; Trinker DS
    Food Drug Cosmet Law J; 1981 Oct; 36(10):517-35. PubMed ID: 11650658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.